Search results
Results from the WOW.Com Content Network
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. [5]
tPA can be manufactured using recombinant biotechnology techniques, producing types of recombinant tissue plasminogen activator (rtPA) such as alteplase, reteplase, and tenecteplase. These drugs are used in clinical medicine to treat embolic or thrombotic stroke , but they are contraindicated and dangerous in cases of hemorrhagic stroke and ...
5340 18815 Ensembl ENSG00000122194 ENSMUSG00000059481 UniProt P00747 P20918 RefSeq (mRNA) NM_001168338 NM_000301 NM_008877 RefSeq (protein) NP_000292 NP_001161810 NP_032903 Location (UCSC) Chr 6: 160.7 – 160.75 Mb Chr 17: 12.6 – 12.64 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Plasminogen activator inhibitor-1 not only functions as an inhibitor, but other roles of PAI-1 ...
Thrombolysis, also called fibrinolytic therapy, is the breakdown of blood clots formed in blood vessels, using medication.It is used in ST elevation myocardial infarction, stroke, and in cases of severe venous thromboembolism (massive pulmonary embolism or extensive deep vein thrombosis).
The effectiveness and risk of tPA is strongly correlated with the delay between stroke onset and tPA delivery ("door-to-needle time"). Current standards recommend for tPA to be delivered within 4,5 hours of onset, while best results occur when treatment is delivered within 90 minutes of onset. [15]
Thus, the CHA 2 DS 2-VASc score is a refinement of CHADS 2 [8] [10] score and extends the latter by including additional common stroke risk factors, that is, age 65–74, female gender and vascular disease. [11] In the CHA 2 DS 2-VASc score, 'age 75 and above' also has extra weight, with 2 points.
Streptokinase is a thrombolytic medication activating plasminogen by nonenzymatic mechanism. [1] As a medication it is used to break down clots in some cases of myocardial infarction (heart attack), pulmonary embolism, and arterial thromboembolism. [2]
MERCI Retriever L5. The MERCI Retriever is a medical device designed to treat Ischemic Strokes.The name is an acronym for Mechanical Embolus Removal in Cerebral Ischemia. . Designed by University of California, Los Angeles in 2001, MERCI was the first device approved in the U.S. to remove blood clots in patients who had acute brain isch